Case Report: Low-Dose Decitabine Plus Anti-PD-1 Inhibitor Camrelizumab for Previously Treated Advanced Metastatic Non-Small Cell Lung Cancer

Background: Although the programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors have markedly changed the strategies of cancer treatment, most patients with advanced non-small cell lung cancer (NSCLC) do not respond to PD-1/PD-L1 monotherapy. Epigenetic drugs have been hypothesized t...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Xin, Zhao, Yongtian, Liu, Yang, Yang, Qingming, Dong, Liang, Wu, Zhiqiang, Nie, Jing, Chen, Deyun, Bai, Miaomiao, Ti, Dongdong, Feng, Kaichao, Han, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649792/
https://www.ncbi.nlm.nih.gov/pubmed/33194624
http://dx.doi.org/10.3389/fonc.2020.558572

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649792/
https://www.ncbi.nlm.nih.gov/pubmed/33194624
http://dx.doi.org/10.3389/fonc.2020.558572

Ejemplares similares